Patent Yard Sign in
Canadian application, no grantCanada

Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents

CA 2453594 A1 · Owner: Yue, Eddy · Inventors: Nugiel, David; Vidwans, Anup; Dimeo, Susan

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

The present invention relates to the synthesis of a new class of indeno1,2cpyrazol-4-ones of formula (I) that are potent inhibitors of the class of enzymes known as cyclin dependent kinases which relate to the catalytic , subunits cdk1-7 and their regulatory subunits know as cyclins A-G. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and …

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed July 16, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 16, 2022.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 16, 2024.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJuly 16, 2002
GrantedNo grant recorded
Term endedJuly 16, 2022
Patent numberCA 2453594 A1
Classification (IPC)C07D231/54 +2 more

Timeline

Timeline From CIPO dates

2003200520072009201120132015201720192021Application filedJuly 16, 2002Term endedJuly 16, 2022

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.